Welcome to our dedicated page for Mimedx Group SEC filings (Ticker: MDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiMedx Group, Inc. filings document the regulatory record for a Florida-incorporated regenerative biomaterials company serving wound care, burn and surgical healthcare markets. Form 8-K reports furnish quarterly and annual operating results, earnings materials, Regulation FD investor presentations and material events tied to business updates.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation, pay-versus-performance data and shareholder voting matters. Recent current reports also document restructuring-related officer changes and temporary compensation reductions for named executive officers, linking governance disclosures to changes in the company’s cost structure.
MiMedx Group, Inc. reported governance updates and 2026 annual meeting results. The board amended the Amended & Restated Bylaws to allow the chief executive officer to serve on up to three boards of directors of public companies.
At the 2026 Annual Meeting, 125,360,965 common shares, representing approximately 84.2% of eligible votes, were present in person or by proxy. Shareholders re‑elected the nominated directors, approved an advisory resolution on executive compensation, and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
BIERMAN JAMES L reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. director James L. Bierman received an annual restricted stock grant of 50,913 shares of common stock on June 10, 2026 at $3.64 per share. The award to this non-employee director vests upon the earlier of 12 months or the next meeting of shareholders, bringing his direct holdings to 263,684 shares. This is a compensation-related equity award, not an open-market purchase.
PUHY DOROTHY E reported acquisition or exercise transactions in this Form 4 filing.
MiMedx Group director Dorothy E. Puhy received a grant of 50,913 shares of common stock at $3.64 per share as an annual restricted stock award for non-employee directors. This compensation-related grant, exempt under Rule 16b-3, will vest upon the earlier of 12 months or the next shareholder meeting. Following the award, she directly holds 108,510 shares of MiMedx common stock.
MIMEDX GROUP, INC. director Todd Newton received an annual restricted stock award, acquiring 50,913 shares of common stock at a reference price of $3.64 per share as director compensation. The grant is exempt under Rule 16b-3 and will vest upon the earlier of 12 months or the next shareholder meeting. Following this award, Newton directly holds 463,684 shares of MIMEDX common stock.
HAWKINS WILLIAM A reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. director William A. Hawkins received an annual restricted stock grant of 50,913 shares of common stock at $3.64 per share. This grant is compensation for his service as a non-employee director and is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next meeting of shareholders. Following this grant, Hawkins directly holds 254,931 shares of MIMEDX common stock.
Olson Tiffany reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. director Tiffany Olson received an award of 50,913 shares of common stock at $3.64 per share as a restricted stock grant for non-employee directors. This equity award vests upon the earlier of 12 months or the next meeting of shareholders, and is exempt under Rule 16b-3. Following the grant, she directly holds 108,510 shares of common stock. This is a compensation-related equity grant rather than an open-market purchase.
MiMedx Group, Inc. files its annual report describing operations centered on placental allografts, a growing wound-care and surgical portfolio, and recent expansion into xenografts and distribution agreements. The report states $719 million aggregate market value of non-affiliate common equity and 148,566,586 shares outstanding as of February 19, 2026.
The company highlights regulatory engagement with the FDA (including an RFD and litigation concerning AXIOFILL), Medicare reimbursement changes effective January 1, 2026 (a new flat rate of $127.14 per cm2), expansion into Japan with reimbursement at 35,100 Yen/cm2, ongoing clinical evidence generation (including an EPIEFFECT RCT), and strategic priorities to broaden products and grow surgical adoption. Revenue seasonality, reliance on donor tissue, and competitive/reimbursement risks are emphasized.
MiMedx Group, Inc. is holding its 2026 annual shareholder meeting as a virtual-only webcast on June 10, 2026, at 9:00 a.m. Eastern time. Shareholders of record at 5:00 p.m. Eastern time on April 13, 2026, may vote.
Investors are asked to elect seven directors, approve on an advisory basis the Company’s executive compensation, and ratify Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026. The Board unanimously recommends voting in favor of all proposals.
The proxy also discusses 2025 performance, including 20% net sales growth, a 12% GAAP net income margin, a 25% adjusted EBITDA margin, and $74 million of operating cash flow, reflecting strong profitability and cash generation alongside strategic product launches and reimbursement changes.
MiMedx Group, Inc. reported first quarter 2026 net sales of $59 million, down 33% from $88 million a year earlier, as new Medicare reimbursement rules severely pressured its Wound segment. Surgical product sales grew 13% year over year to $36.4 million, while Wound sales fell 60% to $22.6 million.
Gross margin declined to 71% from 81%, mainly due to lower Wound pricing and unfavorable mix. The company posted a net loss of $10.9 million, versus $7.0 million of net income in 2025, and Adjusted EBITDA was a loss of $11.6 million, a margin of negative 19.7%.
MiMedx ended March 31, 2026 with $159.8 million in cash and cash equivalents and net cash of $142 million. For 2026, it now expects net sales of $260–$290 million and approximately breakeven Adjusted EBITDA, and continues to target low double-digit annual net sales growth with Adjusted EBITDA margin above 20% longer term.
MiMedx Group reported Q1 2026 net sales of $59.0 million, down 33.1% from $88.2 million a year earlier, and recorded a net loss of $10.9 million versus prior-year net income of $7.0 million. Wound segment sales fell 59.7% to $22.6 million following January 1, 2026 Medicare reimbursement changes for skin substitutes, while Surgical sales grew 13.2% to $36.4 million.
Gross margin compressed to 70.6% from 81.2%, reflecting lower Wound pricing, an unfavorable mix and higher costs. The company ended the quarter with $159.8 million in cash and equivalents, $44.6 million in current liabilities, and $17.6 million of term debt outstanding, leaving its $75.0 million revolver undrawn.
Operating cash flow was $1.9 million, aided by strong receivables collections. MiMedx invested $5.0 million upfront for exclusive U.S. rights to RegenKit Wound Gel and noted a remaining $1.3 million profit-share obligation to TELA Bio. After quarter-end it announced a cost reduction initiative, including a workforce reduction of about 15% and expected one-time charges of roughly $4 million in Q2 2026.